Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
Luye Pharma Group's (HKG:2186) LY03010 injectable for schizophrenia and schizoaffective disorder overcame patent challenges during the new drug application review process by the US Food and Drug Admin
Luye Pharmaceutical (02186.HK) paliperidone palmitate sustained-release suspension injection is expected to be approved for marketing in the US as early as this year
Luye Pharmaceutical Group (2186.HK) updated the latest progress of its new drug marketing review for its paliperidone palmitate sustained-release suspension injection (LY03010) in the US on February 1. Currently, the new drug marketing application (NDA) for this product has been accepted by the US Food and Drug Administration (FDA), and no patent infringement lawsuit has been filed within the time limit stipulated in the US Federal Food, Drug, and Cosmetics Act, which means that the LY03010 project's patent challenge in the FDA approval process has been successful. LY03010 is an innovative preparation independently developed by Luye Pharmaceutical to treat schizophrenia
Luye Pharmaceutical (02186): LY03010 successfully challenged the patent in the US NDA review process
Luye Pharmaceutical (02186) announced that the group controlled the US Food and Drug Administration through 505 (b) (2) channels...
Luye Pharma Group (HKG:2186) Stock Falls 4.7% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Luye Pharma Group Ltd. (HKG:2186) shareholder
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Tianfeng Securities: Target price of HK$4.97 for the initial “buy” rating for Luye Pharmaceuticals (02186)
The Zhitong Finance App learned that Tianfeng Securities released a research report stating that the first payment for Luye Pharmaceuticals (02186) has a “buy” rating. The estimated revenue for 2023-2025 is 61.24/69.91/8.529 billion yuan, and net profit to mother is 6.22/8.09/1,373 billion yuan. Considering the company's obvious advantages in the field of central nervous system and oncology, risperidone and toluvenlafaxine have been approved for listing. Potential varieties such as rotigotine, goserelin, and rubitidine are expected to usher in rapid release after marketing. We are optimistic about the company's development. The target price is HK$4.97. According to the report, the company has matured to go public